Our Commitment to Patients
We are deeply committed to improving the lives of people facing neurological and immunological diseases. We understand that each individual is unique, which is why we prioritize a personalized approach in our research and development. By leveraging advanced scientific methodologies, including machine learning and genetic insights, we strive to identify and develop targeted therapies that address the specific needs of diverse populations with significant unmet medical need. Our focus is on transforming the future of treatment through innovation, collaboration, and a dedication to enhancing patient outcomes.
Current Clinical Trials
We are actively conducting clinical trials to evaluate the safety and efficacy of our investigational therapies. Below are our current clinical trials:
NEULARK Trial
The NEULARK study is evaluating the safety and efficacy of NEU-411 in individuals with LRRK2-driven Parkinson’s disease. This trial aims to investigate whether NEU-411 can potentially slow disease progression and will utilize the first precision medicine patient selection approach in Parkinson’s disease to identify people with LRRK2-driven disease who we believe are most likely to benefit from NEU-411.
NEU-111 Trial
This Phase 1 study is a randomized, double-blind, placebo-controlled clinical trial assessing the safety and tolerability of orally administered NEU-111 in healthy subjects, as well as pharmacodynamic measures of TYK2 target engagement.
